Paradoxical Vitiligo Induced by Adalimumab in Ankylosing Spondylitis With Uveitis: Clinical Management and Therapeutic Considerations

Key Points

• To explore the case of vitiligo induced by adalimumab in a patient with ankylosing spondylitis and uveitis.
• Clinical observation of a patient with ankylosing spondylitis receiving adalimumab
• Assessment of skin changes and management considerations
• Discovery of vitiligo in the patient following the initiation of adalimumab
• Need for careful clinical management due to the paradoxical effect of the treatment